Respiratory Syncytial Virus (RSV) Prevention for the 2026–2027 Season

Synagis® (palivizumab) was voluntarily discontinued by the manufacturer effective December 31, 2025, and is no longer manufactured, distributed, or available for purchase. Providers should use currently recommended RSV prevention options, as clinically appropriate.

The American Academy of Pediatrics (AAP) recommends RSV immunization for:

- All infants younger than 8 months who are born during or entering their first RSV season, unless the infant has documented protection from RSV vaccination during pregnancy.
- Infants and children 8 through 19 months of age who are at high risk of severe RSV disease and are entering their second RSV season.

For infants entering their first RSV season, recommended monoclonal antibody options include Beyfortus® (nirsevimab) and Enflonsia™ (clesrovimab). For eligible high-risk children entering their second RSV season, Beyfortus® (nirsevimab) is the recommended monoclonal antibody option. Product selection and administration should follow current AAP guidance, FDA labeling, and the member's documented maternal RSV vaccination history.

Guidelines/References

1 AAP 2026–2027 RSV Policy Statement
2 AAP RSV Prevention Resources
3 AAP News Synagis Discontinuation

For information on vaccine reimbursement and the Vaccines for Children (VFC) program, providers should refer to the Nevada Medicaid and Nevada Check Up Pharmacy Manual: https://nv.primetherapeutics.com/cms/nvm/static-assets/documents2/document/NV_Pharmacy_Manual.pdf